NIVOLUMAB + IPILIMUMAB

Brand name:

• Opdivo®
• Yervoy®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Unresectable advanced and metastatic cancer

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

Change to existing listing (Matters arising/Matters outstanding)

Comment:

--

Other PBAC consideration:

• NIVOLUMAB IPILIMUMAB

Submission received for:

September 2025 PBAC meeting

Opportunity for consumer comment:

--

PBAC meeting:

Held on 05/09/2025

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

30/09/2025

Lodgement of required documentation:

25/10/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 02/12/2025

Status:

Finalised

Government processes:

Commenced on 17/12/2025

Medicine listed on the PBS:

01/03/2026 (see PBS schedule)